Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1997 Nov;71(11):8893–8898. doi: 10.1128/jvi.71.11.8893-8898.1997

Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.

D Descamps 1, G Collin 1, F Letourneur 1, C Apetrei 1, F Damond 1, I Loussert-Ajaka 1, F Simon 1, S Saragosti 1, F Brun-Vézinet 1
PMCID: PMC192360  PMID: 9343254

Abstract

We investigated the phenotypic and genotypic susceptibility of 11 human immunodeficiency virus type 1 (HIV-1) group O strains to nucleoside and nonnucleoside reverse transcriptase (RT) inhibitors and protease inhibitors in vitro. Phenotypic susceptibility was determined by using a standardized in vitro assay of RT inhibition, taking into account the replication kinetics of each strain. HIV-1 group M and HIV-2 isolates were used as references. DNA from cocultured peripheral blood mononuclear cells was amplified by using pol-specific group O primers and cloned for sequencing. Group O isolates were highly sensitive to nucleoside inhibitors, but six isolates were naturally highly resistant to all of the nonnucleoside RT inhibitors tested. Phylogenetic analysis of the pol gene showed that these isolates formed a separate cluster within group O, and genotypic analysis revealed a tyrosine-to-cysteine substitution at residue 181. Differences in susceptibility to saquinavir and ritonavir (RTV) were not significant between group O and group M isolates, although the 50% inhibitory concentration of RTV for group O isolates was higher than that for the HIV-1 subtype B strains. The study of HIV-1 group O susceptibility to antiretroviral drugs revealed that the viruses tested had specific phenotypic characteristics contrasting with the group M phenotypic expression.

Full Text

The Full Text of this article is available as a PDF (729.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apetrei C., Loussert-Ajaka I., Descamps D., Damond F., Saragosti S., Brun-Vézinet F., Simon F. Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions. AIDS. 1996 Dec;10(14):F57–F60. doi: 10.1097/00002030-199612000-00002. [DOI] [PubMed] [Google Scholar]
  2. Brun-Vézinet F., Ingrand D., Deforges L., Gochi K., Ferchal F., Schmitt M. P., Jung M., Masquelier B., Aubert J., Buffet-Janvresse C. HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. J Virol Methods. 1992 May;37(2):177–188. doi: 10.1016/0166-0934(92)90045-f. [DOI] [PubMed] [Google Scholar]
  3. Carpenter C. C., Fischl M. A., Hammer S. M., Hirsch M. S., Jacobsen D. M., Katzenstein D. A., Montaner J. S., Richman D. D., Sáag M. S., Schooley R. T. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996 Jul 10;276(2):146–154. [PubMed] [Google Scholar]
  4. Charneau P., Borman A. M., Quillent C., Guétard D., Chamaret S., Cohen J., Rémy G., Montagnier L., Clavel F. Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology. 1994 Nov 15;205(1):247–253. doi: 10.1006/viro.1994.1640. [DOI] [PubMed] [Google Scholar]
  5. Descamps D., Collin G., Loussert-Ajaka I., Saragosti S., Simon F., Brun-Vézinet F. HIV-1 group O sensitivity to antiretroviral drugs. AIDS. 1995 Aug;9(8):977–978. [PubMed] [Google Scholar]
  6. Gould K., Britvan L., Dryjanski J. HIV-1 group O infection in the USA. Lancet. 1996 Sep 7;348(9028):680–681. doi: 10.1016/S0140-6736(05)65100-8. [DOI] [PubMed] [Google Scholar]
  7. Gürtler L. G., Hauser P. H., Eberle J., von Brunn A., Knapp S., Zekeng L., Tsague J. M., Kaptue L. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol. 1994 Mar;68(3):1581–1585. doi: 10.1128/jvi.68.3.1581-1585.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hampl H., Sawitzky D., Stöffler-Meilicke M., Groh A., Schmitt M., Eberle J., Gürtler L. First case of HIV-1 subtype 0 infection in Germany. Infection. 1995 Nov-Dec;23(6):369–370. doi: 10.1007/BF01713567. [DOI] [PubMed] [Google Scholar]
  9. Jacobsen H., Hänggi M., Ott M., Duncan I. B., Owen S., Andreoni M., Vella S., Mous J. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis. 1996 Jun;173(6):1379–1387. doi: 10.1093/infdis/173.6.1379. [DOI] [PubMed] [Google Scholar]
  10. Korber B. T., MacInnes K., Smith R. F., Myers G. Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol. 1994 Oct;68(10):6730–6744. doi: 10.1128/jvi.68.10.6730-6744.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Korber B., Myers G. Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses. 1992 Sep;8(9):1549–1560. doi: 10.1089/aid.1992.8.1549. [DOI] [PubMed] [Google Scholar]
  12. Loussert-Ajaka I., Chaix M. L., Korber B., Letourneur F., Gomas E., Allen E., Ly T. D., Brun-Vézinet F., Simon F., Saragosti S. Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France. J Virol. 1995 Sep;69(9):5640–5649. doi: 10.1128/jvi.69.9.5640-5649.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Loussert-Ajaka I., Descamps D., Simon F., Brun-Vézinet F., Ekwalanga M., Saragosti S. Genetic diversity and HIV detection by polymerase chain reaction. Lancet. 1995 Sep 30;346(8979):912–913. doi: 10.1016/s0140-6736(95)92762-x. [DOI] [PubMed] [Google Scholar]
  14. Loussert-Ajaka I., Ly T. D., Chaix M. L., Ingrand D., Saragosti S., Couroucé A. M., Brun-Vézinet F., Simon F. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet. 1994 Jun 4;343(8910):1393–1394. doi: 10.1016/s0140-6736(94)92524-0. [DOI] [PubMed] [Google Scholar]
  15. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P. J., Mo H. M., Markowitz M., Chernyavskiy T., Niu P., Lyons N. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996 Jul;2(7):760–766. doi: 10.1038/nm0796-760. [DOI] [PubMed] [Google Scholar]
  16. Myers G. Tenth anniversary perspectives on AIDS. HIV: between past and future. AIDS Res Hum Retroviruses. 1994 Nov;10(11):1317–1324. doi: 10.1089/aid.1994.10.1317. [DOI] [PubMed] [Google Scholar]
  17. Peeters M., Gueye A., Mboup S., Bibollet-Ruche F., Ekaza E., Mulanga C., Ouedrago R., Gandji R., Mpele P., Dibanga G. Geographical distribution of HIV-1 group O viruses in Africa. AIDS. 1997 Mar 15;11(4):493–498. doi: 10.1097/00002030-199704000-00013. [DOI] [PubMed] [Google Scholar]
  18. Richman D. D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S. A., Sullivan J., Cheeseman S., Barringer K., Pauletti D. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994 Mar;68(3):1660–1666. doi: 10.1128/jvi.68.3.1660-1666.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Richman D. D. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother. 1993 Jun;37(6):1207–1213. doi: 10.1128/aac.37.6.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Schmit J. C., Ruiz L., Clotet B., Raventos A., Tor J., Leonard J., Desmyter J., De Clercq E., Vandamme A. M. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS. 1996 Aug;10(9):995–999. doi: 10.1097/00002030-199610090-00010. [DOI] [PubMed] [Google Scholar]
  21. Soriano V., Gutiérrez M., García-Lerma G., Aguilera O., Mas A., Bravo R., Pérez-Labad M. L., Baquero M., González-Lahoz J. First case of HIV-1 group O infection in Spain. Vox Sang. 1996;71(1):66–66. doi: 10.1046/j.1423-0410.1996.7110066.x. [DOI] [PubMed] [Google Scholar]
  22. Tantillo C., Ding J., Jacobo-Molina A., Nanni R. G., Boyer P. L., Hughes S. H., Pauwels R., Andries K., Janssen P. A., Arnold E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol. 1994 Oct 28;243(3):369–387. doi: 10.1006/jmbi.1994.1665. [DOI] [PubMed] [Google Scholar]
  23. Thompson J. D., Higgins D. G., Gibson T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994 Nov 11;22(22):4673–4680. doi: 10.1093/nar/22.22.4673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Vanden Haesevelde M., Decourt J. L., De Leys R. J., Vanderborght B., van der Groen G., van Heuverswijn H., Saman E. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate. J Virol. 1994 Mar;68(3):1586–1596. doi: 10.1128/jvi.68.3.1586-1596.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES